Product Development (8)

Challenge A leading immuno-oncology biotech company with a pipeline of novel, first-in-class clinical stage assets needed medical support for multiple clinical and medical affairs activities in...

Challenge: A US-based cancer vaccine company developing a peptide-based product was in clinical trials in its lead indication. Recent laboratory research had revealed the target antigens were also...

Challenge A listed biotech company conducting Phase III clinical trials in an oncology indication needed Chief Medical Officer support for multiple clinical activities in Europe and the United States.

Challenge An oncology-focused biopharma company needed support to develop a pipeline of kinase inhibitors in early- and late-stage development.

Challenge: A venture capital-backed platform technology company wanted to develop its internal pipeline of therapeutic oncology candidates, while allowing prospective partners to access the...

Challenge An emerging drug discovery company, with a core expertise in molecular modelling, had developed a small molecule inhibitor for a novel cancer metabolism target. The company was looking to...

Challenge A mid-cap pharma company seeking to establish a biologics pipeline through partnership with a monoclonal antibody development boutique needed an assessment of target opportunities,...

Challenge A university in a developing country wanted advice on best practice for IP protection and technology transfer. Alacrita was engaged to develop a plan for provision of these services.A...

Challenge A start-up that had developed a suite of proprietary antibody technologies needed help to identify accessible cell surface proteins for discovery of candidate therapeutic monoclonal...

Challenge We have conducted multiple due diligence projects, below are three examples:

Challenge A major player in the radiation oncology market was looking for growth opportunities and had identified cancer immunotherapy as a potential opportunity, given the increasing evidence that...

Challenge The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...